Olema Oncology is a clinical-stage biopharmaceutical company that develops targeted therapies for women's cancers. The company's lead product candidate, OP-1250, is a small molecule inhibitor of the estrogen receptor (ER) that is being developed for the treatment of breast cancer. OP-1250 has demonstrated preclinical activity in ER-positive breast cancer models and is currently being evaluated in a Phase 1/2 clinical trial. Olema Oncology is also developing a pipeline of other small molecule inhibitors of the ER and other targets for the treatment of breast and gynecologic cancers.
Highest paying job titles at Olema Oncology include Director, Clinical Pharmacology, Medical Science Liaison, and Patient Safety Director